Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is metabolised inside cancer cells to SN‑38, which binds to the DNA‑topoisomerase I complex. By stabilising this complex, SN‑38 prevents the re‑ligation of single‑strand DNA breaks, leading to accumulation of DNA damage, cell‑cycle arrest and apoptosis of rapidly dividing tumour cells.

The dose of Irinotecan Accord is determined by the prescribing oncologist based on factors such as the patient’s body surface area, disease stage, prior therapies, liver function and overall health. Dosing regimens are individualized and should follow established clinical guidelines or protocol specifications.

Safety data for irinotecan in pregnancy and lactation are limited. The product is classified as having unknown pregnancy risk, and it is generally avoided unless the potential benefit justifies the potential fetal or neonatal risk. Breastfeeding is also not recommended while receiving treatment.

To order Irinotecan Accord, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as oxaliplatin (a platinum compound) or 5‑fluorouracil (a pyrimidine analogue). Its unique mechanism targets DNA‑topoisomerase I, offering an alternative pathway for tumour control, especially in patients who have progressed on other regimens.

Irinotecan Accord should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product must not be frozen or shaken. Prior to administration, it should be inspected for particulate matter and prepared under aseptic conditions according to the manufacturer’s instructions.

Irinotecan Accord is given as an intravenous infusion, typically over 30 to 90 minutes depending on the protocol. The infusion is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring of vital signs and supportive care measures such as anti‑emetics and hydration.

The most serious risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea or colitis, cholinergic syndrome, and significant hepatic toxicity. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Irinotecan Accord should be avoided in patients with known hypersensitivity to irinotecan or any of its excipients, in those with severe hepatic impairment, and in individuals who are pregnant or breastfeeding unless the potential benefit outweighs the risk. Caution is also advised for patients with pre‑existing bone‑marrow suppression.